Renasant Bank Novo Nordisk A S Transaction History

Renasant Bank

$138 Million
Q3 2024

A detailed history of Renasant Bank transactions in Novo Nordisk A S stock. As of the latest transaction made, Renasant Bank holds 5,502 shares of NVO stock, worth $564,670. This represents 0.47% of its overall portfolio holdings.

Number of Shares

5,502

Previous 4,583 20.05%

Holding current value

$564,670

Previous $654,000 0.15%

% of portfolio

0.47%

Previous 0.48%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	BUY	$119.07 - $145.42 $109,425 - $133,640	919 Added 20.05%	5,502 $655,000
Q2 2024 Aug 09, 2024	SELL	$122.71 - $146.91 $17,302 - $20,714	-141 Reduced 2.98%	4,583 $654,000
Q1 2024 May 09, 2024	SELL	$102.11 - $135.92 $21,953 - $29,222	-215 Reduced 4.35%	4,724 $606,000
Q4 2023 Feb 12, 2024	BUY	$87.78 - $105.45 $6,144 - $7,381	70 Added 1.44%	4,939 $510,000
Q3 2023 Nov 01, 2023	BUY	$90.94 - $199.54 $207,252 - $454,751	2,279 Added 87.99%	4,869 $442,000
Q2 2023 Aug 01, 2023	SELL	$155.98 - $172.65 $98,735 - $109,287	-633 Reduced 19.64%	2,590 $419,000
Q1 2023 May 05, 2023	BUY	$132.34 - $159.14 $44,863 - $53,948	339 Added 11.75%	3,223 $512,000
Q4 2022 Feb 09, 2023	BUY	$102.55 - $135.33 $7,691 - $10,149	75 Added 2.67%	2,884 $390,000
Q3 2022 Nov 03, 2022	BUY	$95.28 - $116.93 $23,343 - $28,647	245 Added 9.56%	2,809 $280,000
Q2 2022 Aug 03, 2022	BUY	$103.24 - $121.81 $1,755 - $2,070	17 Added 0.67%	2,564 $286,000
Q4 2021 Feb 11, 2022	BUY	$95.88 - $117.08 $244,206 - $298,202	2,547 New	2,547 $285,000
Q3 2021 Oct 12, 2021	SELL	$84.42 - $106.62 $206,575 - $260,899	-2,447 Closed	0 $0
Q2 2021 Jul 19, 2021	BUY	$67.66 - $84.76 $165,564 - $207,407	2,447 New	2,447 $204,000

Others Institutions Holding NVO

# of Institutions

1,952

Shares Held

320M

Call Options Held

5.49M

Put Options Held

7.78M

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $232B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renasant Bank, based on Form 13F filings with the SEC.

News

Stay updated on Renasant Bank with notifications on news.

Account